Lecanemab (Leqembi®) for the Treatment of Alzheimer’s Disease

Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for lecanemab (Leqembi) for adult patients with Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, who are apolipoprotein E ε4 (ApoE ε4) noncarriers or heterozygotes, and who have confirmed amyloid pathology. Lecanemab should be prescribed by clinicians with expertise in diagnosing, managing and treating patients with mild cognitive impairment or mild dementia stage of disease.

  • Introduction
  • Experience with Disease
  • Experience with Other Treatments
  • Drug-Related Questions
  • Conclusion
  • Your Voice Feedback
  • Preview
  • Complete
1 of 8

Thank you for taking the time to fill out BC PharmaCare’s public survey on drugs being reviewed for coverage. You may submit a survey only once. If you do not complete the survey or navigate away from the page while entering your responses, you can return to the last unsaved page and complete the questionnaire.

To protect your privacy, do not include in your responses the names of individuals or companies, locations, or any other information that might identify them or anyone else.

Note: mandatory questions are flagged with a red asterisk (*). To have your input accepted, you must complete the Confirmation of Eligibility and Conflict of Interest sections and you must be a resident of BC or represent patients who reside in the province. You do not need to answer all the optional questions. You need only answer those that you think apply to you.

The patient input surveys are reserved for patients, caregivers, or patient groups who have experience with the disease in question. Please select the category you identify as below:
I am a resident of British Columbia.
I am a caregiver for someone who is resident of British Columbia.
I am a representative of a patient group that advocates for residents of British Columbia.
Is your patient group registered with the Ministry of Health to provide input to our drug reviews?
If not, please register your patient group here.
Do you have any conflicts of interest to declare?

To make sure the drug review process is objective and credible, everyone who provides input has to tell us about any possible conflicts of interest.

A conflict of interest exists if you or an immediate family member might benefit from the outcome of PharmaCare's drug review. For example, if you own stock in the company that makes a drug, there could be a financial benefit if PharmaCare decides to cover the drug.

Examples of conflicts of interest include, but are not limited to, financial support from the pharmaceutical industry (e.g., educational or research grants, honoraria, gifts and salary), as well as affiliations or commercial relationships with drug manufacturers or other interest groups.

Even if you or an immediate family member has a conflict of interest, your input will still be considered as long as you declare the conflict of interest in your answers to the questions. All information you provide is protected under the Freedom of Information and Protection of Privacy Act.
Have you read the drug information sheet?
If not, please take five minutes to read the information sheet found on the Drugs/devices now being reviewed by BC PharmaCare table on the Your Voice webpage.